Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MHLW Set to Clarify Review Procedures for Companion Diagnostics
November 21, 2012
-
REGULATORY GRU to Propose that Welfare Beneficiaries Be Required to Use Generics as a Rule
November 20, 2012
-
BUSINESS Novartis to Revamp Marketing Structure in CNS Field, Shift from SOV
November 19, 2012
-
BUSINESS E Keppra Grabs 20% Share of Domestic Anti-Epileptic Drug Market; Sales Growing Rapidly
November 19, 2012
-
REGULATORY CSIMC Subcommittee Eyes Price Cuts for Long-Listed Drugs with Slow Generic Penetration
November 16, 2012
-
REGULATORY CSIMC OKs Listing for 15 APIs/22 Products; Peak Sales Estimated at 32.6 Billion Yen for Lotriga
November 15, 2012
-
BUSINESS Japan’s 25 Major Drug Makers Log Contrasting Domestic Biz Results on Varying New Product Performances
November 14, 2012
-
REGULATORY Health Coverage for OTC-Like Drugs Up for Review Yet Again
November 13, 2012
-
REGULATORY Zoledronic Acid, Sildenafil Subject to Pilot Study on Generic RMPs
November 12, 2012
-
BUSINESS Time Will Tell Whether Once-monthly Products Ultimately Dominate or Merely Provide Another Option in the BP Market
November 12, 2012
-
BUSINESS Four Companies Discontinue Marketing Atelec Generics Due to Halt in Supplies of Bulk Drug Substance
November 9, 2012
-
REGULATORY Drug Makers Invited to Join in Intractable Disease Drug Discovery Research Using iPS Cells from This Fiscal Year
November 8, 2012
-
BUSINESS Takeda to Buy Envoy of US to Reinforce Drug Discovery Prowess
November 7, 2012
-
BUSINESS Abbott Japan Spins Off New Drug Biz, Establishes New Firm “AbbVie”
November 6, 2012
-
BUSINESS Sawai’s Status Improved Within Mediceo by Utilizing ARs
November 6, 2012
-
BUSINESS Domestic Drug Makers’ Major Products See Sharp Declines in 1st Half; Sales of Aricept, Lipitor Down 30%
November 5, 2012
-
BUSINESS “Lecture Meeting Fever” as Companies Seek New Ways to Interact with Doctors Under Tougher Restrictions on Settai
November 5, 2012
-
BUSINESS Sales Target for Prasugrel Achievable Despite Add’l Indication Dropped: Daiichi Sankyo Pres. Nakayama
November 2, 2012
-
BUSINESS Takeda’s Japan Sales Ratio Likely to Fall to Mid-30% Range: President Hasegawa
November 1, 2012
-
BUSINESS Mochida, MTPC See Signs of Sales Growth for Lexapro after Lifting of Long-Term Prescription Ban
October 31, 2012
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…